| Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype. | |
| | |
MedLine Citation:
|
PMID: 9517378 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. In this study we investigated whether long-term trimetazidine (anti-ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy. 2. MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform patterns were studied in cardiac muscle from cardiomyopathic hamsters (CMH) of the BIO 14:6 strain during the time course of the disease and compared with those of healthy golden hamsters (F1B). The correlation between myosin profile and Ca2+-activated ATPase activity was determined from 220 days. 3. At the stage of insufficiency (350 days), CMH presented the most abnormal phenotype with 53% V1-24% V3 compared to 79% V1-7% V3 (P<0.001), in F1B. Trimetazidine was administered to cardiomyopathic hamsters from the early stage of active disease (30 days) to the congestive stages (220-350 days). Within 65 days, trimetazidine treatment, in CMH and F1B, reduced V1 to a low level (53% and 62%, respectively), which remained constant throughout the treatment. This level was similar to that in 220 and 350 days-old untreated-CMH. In sharp contrast, a standard calcium blocker, verapamil, administered to CMH in the same conditions resulted in a higher V1 (about 70%) and higher global myosin ATPase activity from 220 days. 4. Previous results in terms of hypertrophy and survival, compared to these results, suggest that verapamil and trimetazidine treatments reveal a dissociation between ventricular hypertrophy and isomyosin distribution. In addition, the shift in favour of V3 may not necessarily be an aggravating factor of the disease but an adaptative compensatory event. |
| | |
Authors:
|
N D'hahan; K Taouil; C Janmot; J E Morel |
Related Documents
:
|
15368798 - Recent insights in the development of organ damage caused by hypertension. 15170858 - Nitric oxide and the enigma of cardiac hypertrophy. 20643208 - Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters ... 8184288 - Valve replacement for aortic stenosis: the curative potential of early operation. 12174028 - Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angioten... 7178228 - Interaction of ouabain and propranolol in the central nervous system. neurally-mediated... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of pharmacology Volume: 123 ISSN: 0007-1188 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 1998 Feb |
Date Detail:
|
Created Date: 1998-04-16 Completed Date: 1998-04-16 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 611-6 Citation Subset: IM |
Affiliation:
|
Laboratoire de Biologie, Ecole Centrale Paris, Châtenay-Malabry, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Calcium Channel Blockers / therapeutic use* Calcium-Transporting ATPases / metabolism Cardiomyopathies / drug therapy*, enzymology, genetics Cricetinae Electrophoresis, Polyacrylamide Gel Mesocricetus Myosins / genetics*, isolation & purification Phenotype Trimetazidine / therapeutic use* Vasodilator Agents / therapeutic use* Verapamil / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Calcium Channel Blockers; 0/Vasodilator Agents; 5011-34-7/Trimetazidine; 52-53-9/Verapamil; EC 3.6.1.8/Calcium-Transporting ATPases; EC 3.6.4.1/Myosins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
Next Document: Mediators and mechanisms of relaxation in rabbit urethral smooth muscle.